A bipartisan group of members of Congress have filed an amendment to a large-scale military bill that would extend a psychedelics research effort at the Department of Defense (DOD) for an additional six years.
Reps. Morgan Luttrell (R-TX), Jack Bergman (R-MI), Derrick Van Orden (R-WI), Mike Ezell (R-MS), Troy Carter (D-LA) and Morgan McGarvey (D-KY) are proposing to amend the National Defense Authorization Act (NDAA) for Fiscal Year 2027 to include language expanding DOD studies on psychedelics that were first authorized under the earlier 2024 NDAA.
That program, signed into law by then-President Joe Biden, directed DOD to establish a process by which active duty service members with post-traumatic stress disorder (PTSD) or traumatic brain injury could participate in clinical trials involving psilocybin, MDMA, ibogaine, 5-MeO-DMT and “qualified plant-based alternative therapies.”
As enacted, it only required the secretary of defense to issue updated reports on progress within one year of the law passing and then annually for three years after that. The new amendment would replace “three years” in the law with “nine years.” It also specifies that DOD would have to “extend the performance of research conducted using funding awarded under this section to September 30, 2033.”
The previously enacted
Read full article on Marijuana Moment
